NCI awards UAB $2.3M brain-tumor SPORE grant

October 06, 2017

Other pilot projects include designing a clinical trial to test a small-molecule inhibitor of a critical enzyme that is overactive in brain tumors and also re-purposing an older drug with a proven safety history for treating malaria and testing its outcomes in patients with anaplastic gliomas.

The research team of 14 investigators from seven departments at UAB will comprise the interactive multi-disciplinary research team. The NCI SPORE program was started in 1992 as a way to promote interdisciplinary research and speed the transition of basic science findings to the clinical testing arena with the hope of reducing cancer-death rates and improving survival.

"This award reflects the strength of our research team to rapidly move innovative discoveries from our laboratories to our patient clinics," says Edward Partridge, M.D., director of the UAB Comprehensive Cancer Center. "It's a perfect example of our ability to collaboratively work together and conduct groundbreaking, leading-edge translational research."

Five core facilities will provide administrative assistance, maintain a patient clinical specimen repository to allow direct studies on tumor tissues, design and conduct clinical trials, provide biostatistical and bioinformatic support and conduct preclinical studies of new therapies in animal models of brain tumors to ensure they are safe and effective for human studies.

Source UAB Comprehensive Cancer Center